3.8

CiteScore

2.4

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 38 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Abstract
Acknowledgments
References
Related Articles
Supplements
Juan Zhou, Yiran Xu, Luyao Wang, Yu Cong, Ke Huang, Xinxing Pan, Guangquan Liu, Wenqu Li, Chenchen Dai, Pengfei Xu, Xuemei Jia. LncRNA IDH1-AS1 sponges miR-518c-5p to suppress proliferation of epithelial ovarian cancer cell by targeting RMB47[J]. The Journal of Biomedical Research, 2024, 38(1): 51-65. DOI: 10.7555/JBR.37.20230097
Citation: Juan Zhou, Yiran Xu, Luyao Wang, Yu Cong, Ke Huang, Xinxing Pan, Guangquan Liu, Wenqu Li, Chenchen Dai, Pengfei Xu, Xuemei Jia. LncRNA IDH1-AS1 sponges miR-518c-5p to suppress proliferation of epithelial ovarian cancer cell by targeting RMB47[J]. The Journal of Biomedical Research, 2024, 38(1): 51-65. DOI: 10.7555/JBR.37.20230097
shu

LncRNA IDH1-AS1 sponges miR-518c-5p to suppress proliferation of epithelial ovarian cancer cell by targeting RMB47

  • 1.

    Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210004, China

  • 2.

    Nanjing Maternity and Child Health Medical Institute, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210004, China

More Information
  • Corresponding author:

    Xuemei Jia, Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, 123 Mochou Rd, Nanjing, Jiangsu 210004, China. E-mail: xmjia@njmu.edu.cn; Pengfei Xu, Nanjing Maternity and Child Health Medical Institute, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, 123 Mochou Rd, Nanjing, Jiangsu 210004, China. E-mail: pengfeixu@njmu.edu.cn

  • △These authors contributed equally to this work.

  • Received Date: April 17, 2023
  • Revised Date: August 21, 2023
  • Accepted Date: August 28, 2023
  • Available Online: September 01, 2023
  • Published Date: November 19, 2023
    Abstract

  • Long noncoding RNA (lncRNA) IDH1 antisense RNA 1 (IDH1-AS1) is involved in the progression of multiple cancers, but its role in epithelial ovarian cancer (EOC) is unknown. Therefore, we investigated the expression levels of IDH1-AS1 in EOC cells and normal ovarian epithelial cells by quantitative real-time PCR (qPCR). We first evaluated the effects of IDH1-AS1 on the proliferation, migration, and invasion of EOC cells through cell counting kit-8, colony formation, EdU, transwell, wound-healing, and xenograft assays. We then explored the downstream targets of IDH1-AS1 and verified the results by a dual-luciferase reporter, qPCR, rescue experiments, and Western blotting. We found that the expression levels of IDH1-AS1 were lower in EOC cells than in normal ovarian epithelial cells. High IDH1-AS1 expression of EOC patients from the Gene Expression Profiling Interactive Analysis database indicated a favorable prognosis, because IDH1-AS1 inhibited cell proliferation and xenograft tumor growth of EOC. IDH1-AS1 sponged miR-518c-5p whose overexpression promoted EOC cell proliferation. The miR-518c-5p mimic also reversed the proliferation-inhibiting effect induced by IDH1-AS1 overexpression. Furthermore, we found that RNA binding motif protein 47 (RBM47) was the downstream target of miR-518c-5p, that upregulation of RBM47 inhibited EOC cell proliferation, and that RBM47 overexpressing plasmid counteracted the proliferation-promoting effect caused by the IDH1-AS1 knockdown. Taken together, IDH1-AS1 may suppress EOC cell proliferation and tumor growth via the miR-518c-5p/RBM47 axis.

    • FullText(HTML)

  • We acknowledge and appreciate our institutional colleagues for their experimental technical support.

    CLC number: R73-3, Document code: A

    The authors reported no conflict of interests.

    • References (35)
  • [1]
    Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17–48. doi: 10.3322/caac.21763
    [2]
    Wang M, Zhang J, Wu Y. Tumor metabolism rewiring in epithelial ovarian cancer[J]. J Ovarian Res, 2023, 16(1): 108. doi: 10.1186/s13048-023-01196-0
    [3]
    Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer[J]. BMJ, 2020, 371: m3773. doi: 10.1136/bmj.m3773
    [4]
    Salamini-Montemurri M, Lamas-Maceiras M, Lorenzo-Catoira L, et al. Identification of lncRNAs deregulated in epithelial ovarian cancer based on a gene expression profiling meta-analysis[J]. Int J Mol Sci, 2023, 24(13): 10798. doi: 10.3390/ijms241310798
    [5]
    Zhao S, Zhang X, Chen S, et al. Natural antisense transcripts in the biological hallmarks of cancer: powerful regulators hidden in the dark[J]. J Exp Clin Cancer Res, 2020, 39(1): 187. doi: 10.1186/s13046-020-01700-0
    [6]
    Xu F, Huang M, Chen Q, et al. LncRNA HIF1A-AS1 promotes gemcitabine resistance of pancreatic cancer by enhancing glycolysis through modulating the AKT/YB1/HIF1α pathway[J]. Cancer Res, 2021, 81(22): 5678–5691. doi: 10.1158/0008-5472.CAN-21-0281
    [7]
    Yang L, Chen Y, Liu N, et al. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN[J]. J Hematol Oncol, 2021, 14(1): 46. doi: 10.1186/s13045-021-01059-5
    [8]
    Liu Y, Zhang P, Wu Q, et al. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and ΔNp63[J]. Nat Commun, 2021, 12(1): 5232. doi: 10.1038/s41467-021-25552-0
    [9]
    Xiang S, Gu H, Jin L, et al. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect[J]. Proc Natl Acad Sci U S A, 2018, 115(7): E1465–E1474. doi: 10.1073/pnas.1711257115
    [10]
    Zhang N, Li Z, Bai F, et al. PAX5-induced upregulation of IDH1-AS1 promotes tumor growth in prostate cancer by regulating ATG5-mediated autophagy[J]. Cell Death Dis, 2019, 10(10): 734. doi: 10.1038/s41419-019-1932-3
    [11]
    Wang J, Quan Y, Lv J, et al. LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma[J]. Biochem Cell Biol, 2020, 98(5): 556–564. doi: 10.1139/bcb-2019-0465
    [12]
    Braga EA, Fridman MV, Moscovtsev AA, et al. LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms[J]. Int J Mol Sci, 2020, 21(22): 8855. doi: 10.3390/ijms21228855
    [13]
    Klar M, Hasenburg A, Hasanov M, et al. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO[J]. Eur J Cancer, 2016, 66: 114–124. doi: 10.1016/j.ejca.2016.07.014
    [14]
    Chang LC, Huang CF, Lai MS, et al. Prognostic factors in epithelial ovarian cancer: a population-based study[J]. PLoS One, 2018, 13(3): e0194993. doi: 10.1371/journal.pone.0194993
    [15]
    Rosendahl M, Høgdall CK, Mosgaard BJ. Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian, fallopian tube, and primary peritoneal cancer[J]. Int J Gynecol Cancer, 2016, 26(4): 680–687. doi: 10.1097/IGC.0000000000000675
    [16]
    Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage[J]. J Natl Cancer Inst, 2019, 111(1): 60–68. doi: 10.1093/jnci/djy071
    [17]
    Martinez A, Pomel C, Filleron T, et al. Prognostic relevance of celiac lymph node involvement in ovarian cancer[J]. Int J Gynecol Cancer, 2014, 24(1): 48–53. doi: 10.1097/IGC.0000000000000041
    [18]
    Ataseven B, Grimm C, Harter P, et al. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 135(3): 435–440. doi: 10.1016/j.ygyno.2014.10.003
    [19]
    Wu S, Ding L, Xu H, et al. The long non-coding RNA IDH1-AS1 promotes prostate cancer progression by enhancing IDH1 enzyme activity[J]. Onco Targets Ther, 2020, 13: 7897–7906. doi: 10.2147/OTT.S251915
    [20]
    Chen L. Linking long noncoding RNA localization and function[J]. Trends Biochem Sci, 2016, 41(9): 761–772. doi: 10.1016/j.tibs.2016.07.003
    [21]
    Fernandes JCR, Acuña SM, Aoki JI, et al. Long non-coding RNAs in the regulation of gene expression: physiology and disease[J]. Non-Coding RNA, 2019, 5(1): 17. doi: 10.3390/ncrna5010017
    [22]
    Fan Y, Wang L, Han X, et al. LncRNA ASB16-AS1 accelerates cellular process and chemoresistance of ovarian cancer cells by regulating GOLM1 expression via targeting miR-3918[J]. Biochem Biophys Res Commun, 2023, 675: 1–9. doi: 10.1016/j.bbrc.2023.06.068
    [23]
    Su M, Huang P, Li Q. Long noncoding RNA SNHG6 promotes the malignant phenotypes of ovarian cancer cells via miR-543/YAP1 pathway[J]. Heliyon, 2023, 9(5): e16291. doi: 10.1016/j.heliyon.2023.e16291
    [24]
    Li Y, Zhu X, Zhang C, et al. Long noncoding RNA FTX promotes epithelial-mesenchymal transition of epithelial ovarian cancer through modulating miR-7515/TPD52 and activating Met/Akt/mTOR[J]. Histol Histopathol, 2023, 9: 18620. doi: 10.14670/HH-18-620
    [25]
    Flor I, Bullerdiek J. The dark side of a success story: microRNAs of the C19MC cluster in human tumours[J]. J Pathol, 2012, 227(3): 270–274. doi: 10.1002/path.4014
    [26]
    Dyrskjøt L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro[J]. Cancer Res, 2009, 69(11): 4851–4860. doi: 10.1158/0008-5472.CAN-08-4043
    [27]
    Zhao J, Yang J, Lin J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis[J]. Childs Nerv Syst, 2009, 25(1): 13–20. doi: 10.1007/s00381-008-0701-x
    [28]
    Kinouchi M, Uchida D, Kuribayashi N, et al. Involvement of miR-518c-5p to growth and metastasis in oral cancer[J]. PLoS One, 2014, 9(12): e115936. doi: 10.1371/journal.pone.0115936
    [29]
    He J, Han Z, Luo J, et al. Hsa_Circ_0007843 acts as a miR-518c-5p sponge to regulate the migration and invasion of colon cancer SW480 cells[J]. Front Genet, 2020, 11: 9. doi: 10.3389/fgene.2020.00009
    [30]
    Fossat N, Radziewic T, Jones V, et al. Conditional restoration and inactivation of Rbm47 reveal its tissue-context requirement for viability and growth[J]. Genesis, 2016, 54(3): 115–122. doi: 10.1002/dvg.22920
    [31]
    Radine C, Peters D, Reese A, et al. The RNA-binding protein RBM47 is a novel regulator of cell fate decisions by transcriptionally controlling the p53-p21-axis[J]. Cell Death Differ, 2020, 27(4): 1274–1285. doi: 10.1038/s41418-019-0414-6
    [32]
    Sakurai T, Isogaya K, Sakai S, et al. RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma[J]. Oncogene, 2016, 35(38): 5000–5009. doi: 10.1038/onc.2016.35
    [33]
    Guo T, You K, Chen X, et al. RBM47 inhibits hepatocellular carcinoma progression by targeting UPF1 as a DNA/RNA regulator[J]. Cell Death Discov, 2022, 8(1): 320. doi: 10.1038/s41420-022-01112-3
    [34]
    Qin Y, Sun W, Wang Z, et al. RBM47/SNHG5/FOXO3 axis activates autophagy and inhibits cell proliferation in papillary thyroid carcinoma[J]. Cell Death Dis, 2022, 13(3): 270. doi: 10.1038/s41419-022-04728-6
    [35]
    Shen D, Jiang Y, Li J, et al. The RNA-binding protein RBM47 inhibits non-small cell lung carcinoma metastasis through modulation of AXIN1 mRNA stability and Wnt/β-catentin signaling[J]. Surg Oncol, 2020, 34: 31–39. doi: 10.1016/j.suronc.2020.02.011
    • Related Articles

  • Related Articles

    [1]Fei Qin, Hao Yu, Changrong Xu, Huihui Chen, Jianling Bai. Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis[J]. The Journal of Biomedical Research, 2018, 32(1): 30-38. DOI: 10.7555/JBR.32.20170080
    [2]Xu Hu, Linfei Jiang, Chenhui Tang, Yuehong Ju, Li Jiu, Yongyue Wei, Li Guo, Yang Zhao. Association of three single nucleotide polymorphisms of ESR1 with breast cancer susceptibility: a meta-analysis[J]. The Journal of Biomedical Research, 2017, 31(3): 213-225. DOI: 10.7555/JBR.31.20160087
    [3]Wei Qian, Kuanfeng Xu, Wenting Jia, Ling Lan, Xuqin Zheng, Xueyang Yang, Dai Cui. Association between TSHR gene polymorphism and the risk of Graves' disease: a meta-analysis[J]. The Journal of Biomedical Research, 2016, 30(6): 466-475. DOI: 10.7555/JBR.30.20140144
    [4]Peng Zou, Lin Zhao, Haitao Xu, Ping Chen, Aihua Gu, Ning Liu, Peng Zhao, Ailin Lu. Hsa-mir-499 rs3746444 polymorphism and cancer risk: a meta-analysis[J]. The Journal of Biomedical Research, 2012, 26(4): 253-259. DOI: 10.7555/JBR.26.20110122
    [5]Zhiqiang Yin, Jiali Xu, Dan Luo. Efficacy and tolerance of tacrolimus and pimecrolimus for atopic dermatitis: a meta-analysis[J]. The Journal of Biomedical Research, 2011, 25(6): 385-391. DOI: 10.1016/S1674-8301(11)60051-1
    [6]Liang Zong, Ping Chen, Yinbing Chen, Guohao Shi. Pouch Roux-en-Y vs No Pouch Roux-en-Y following total gastrectomy: a meta-analysis based on 12 studies[J]. The Journal of Biomedical Research, 2011, 25(2): 90-99. DOI: 10.1016/S1674-8301(11)60011-0
    [7]Lifeng Zhang, Ning Shao, Qianqian Yu, Lixin Hua, Yuanyuan Mi, Ninghan Feng. Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis[J]. The Journal of Biomedical Research, 2011, 25(1): 25-32. DOI: 10.1016/S1674-8301(11)60003-1
    [8]Donghua Li, Jie Wu. Association of the MTHFR C677T polymorphism and bone mineral density in postmenopausal women: a meta-analysis[J]. The Journal of Biomedical Research, 2010, 24(6): 417-423. DOI: 10.1016/S1674-8301(10)60056-5
    [9]Yuanyuan Mi, Qianqian Yu, Zhichao Min, Bin Xu, Lifeng Zhang, Wei Zhang, Ninghan Feng, Lixin Hua. Arg462Gln and Asp541Glu polymorphisms in ribonuclease L and prostate cancer risk: a meta-analysis[J]. The Journal of Biomedical Research, 2010, 24(5): 365-373. DOI: 10.1016/S1674-8301(10)60049-8
    [10]Bingbing Wei, Yunyun Zhang, Bo Xi, Junkai Chang, Jinming Bai, Jiantang Su. CYP17 T27C polymorphism and prostate cancer risk:a meta-analysis based on 31 studies[J]. The Journal of Biomedical Research, 2010, 24(3): 233-241.
    • Supplements (1)

  • Other Related Supplements

  • Cited by

    Periodical cited type(25)

    1. Song P, Liu T, Zhang Y, et al. Traditional Chinese medicine in the treatment of breast Cancer. Mol Cancer, 2025, 24(1): 209. DOI:10.1186/s12943-025-02416-5
    2. Sumorek-Wiadro J, Kapral-Piotrowska J, Zając A, et al. Proapoptotic and antimigration properties of osthole in combination with LY294002 against human glioma cells. Naunyn Schmiedebergs Arch Pharmacol, 2025, 398(3): 3147-3161. DOI:10.1007/s00210-024-03424-w
    3. Kordulewska NK, Król-Grzymała A. The Effect of Osthole on Transient Receptor Potential Channels: A Possible Alternative Therapy for Atopic Dermatitis. J Inflamm Res, 2024, 17: 881-898. DOI:10.2147/JIR.S425978
    4. Kordulewska NK, Król-Grzymała A. The Effect of Osthole on Transient Receptor Potential Channels: A Possible Alternative Therapy for Atopic Dermatitis. J Inflamm Res, 2024, 17: 881-898. DOI:10.2147/JIR.S425978
    5. Naeem A, Hu P, Yang M, et al. Natural Products as Anticancer Agents: Current Status and Future Perspectives. Molecules, 2022, 27(23): 8367. DOI:10.3390/molecules27238367
    6. Naeem A, Hu P, Yang M, et al. Natural Products as Anticancer Agents: Current Status and Future Perspectives. Molecules, 2022, 27(23): 8367. DOI:10.3390/molecules27238367
    7. Kordulewska NK, Topa J, Rozmus D, et al. Effects of Osthole on Inflammatory Gene Expression and Cytokine Secretion in Histamine-Induced Inflammation in the Caco-2 Cell Line. Int J Mol Sci, 2021, 22(24): 13634. DOI:10.3390/ijms222413634
    8. Mei J, Wang T, Zhao S, et al. Osthole Inhibits Breast Cancer Progression through Upregulating Tumor Suppressor GNG7. J Oncol, 2021, 2021: 6610511. DOI:10.1155/2021/6610511
    9. Mei J, Wang T, Zhao S, et al. Osthole Inhibits Breast Cancer Progression through Upregulating Tumor Suppressor GNG7. J Oncol, 2021, 2021: 6610511. DOI:10.1155/2021/6610511
    10. Abosharaf HA, Diab T, Atlam FM, et al. Osthole extracted from a citrus fruit that affects apoptosis on A549 cell line by histone deacetylasese inhibition (HDACs). Biotechnol Rep (Amst), 2020, 28: e00531. DOI:10.1016/j.btre.2020.e00531
    11. Ávalos-Moreno M, López-Tejada A, Blaya-Cánovas JL, et al. Drug Repurposing for Triple-Negative Breast Cancer. J Pers Med, 2020, 10(4): 200. DOI:10.3390/jpm10040200
    12. Kordulewska NK, Topa J, Tańska M, et al. Modulatory Effects of Osthole on Lipopolysaccharides-Induced Inflammation in Caco-2 Cell Monolayer and Co-Cultures with THP-1 and THP-1-Derived Macrophages. Nutrients, 2020, 13(1): 123. DOI:10.3390/nu13010123
    13. Ye J, Sun D, Yu Y, et al. Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway. Aging (Albany NY), 2020, 12(14): 14406-14417. DOI:10.18632/aging.103484
    14. Wang B, Shen C, Li Y, et al. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling. Onco Targets Ther, 2019, 12: 5751-5765. DOI:10.2147/OTT.S208924
    15. Wang B, Shen C, Li Y, et al. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling. Onco Targets Ther, 2019, 12: 5751-5765. DOI:10.2147/OTT.S208924
    16. Yang Y, Ren F, Tian Z, et al. Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway. Front Pharmacol, 2018, 9: 1392. DOI:10.3389/fphar.2018.01392
    17. Liu Y, Dong X, Wang W, et al. Molecular Mechanisms of Apoptosis in HepaRG Cell Line Induced by Polyphyllin VI via the Fas Death Pathway and Mitochondrial-Dependent Pathway. Toxins (Basel), 2018, 10(5): 201. DOI:10.3390/toxins10050201
    18. Zhang S, Huang Q, Cai X, et al. Osthole Ameliorates Renal Fibrosis in Mice by Suppressing Fibroblast Activation and Epithelial-Mesenchymal Transition. Front Physiol, 2018, 9: 1650. DOI:10.3389/fphys.2018.01650
    19. Liu Y, Dong X, Wang W, et al. Molecular Mechanisms of Apoptosis in HepaRG Cell Line Induced by Polyphyllin VI via the Fas Death Pathway and Mitochondrial-Dependent Pathway. Toxins (Basel), 2018, 10(5): 201. DOI:10.3390/toxins10050201
    20. Zhu X, Song X, Xie K, et al. Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma. Int J Mol Med, 2017, 40(4): 1143-1151. DOI:10.3892/ijmm.2017.3113
    21. Feng H, Lu JJ, Wang Y, et al. Osthole inhibited TGF β-induced epithelial-mesenchymal transition (EMT) by suppressing NF-κB mediated Snail activation in lung cancer A549 cells. Cell Adh Migr, 2017, 11(5-6): 464-475. DOI:10.1080/19336918.2016.1259058
    22. Li H, Wang Q, Dong L, et al. Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis. J Exp Clin Cancer Res, 2015, 34: 137. DOI:10.1186/s13046-015-0252-4
    23. Yang M, Zhu H, Hu T, et al. Association of CCND1 gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis. Int J Clin Exp Med, 2015, 8(8): 12983-8.
    24. Ying J, Xu H, Wu D, et al. Emodin induces apoptosis of human osteosarcoma cells via mitochondria- and endoplasmic reticulum stress-related pathways. Int J Clin Exp Pathol, 2015, 8(10): 12837-44.
    25. Yang M, Zhu H, Hu T, et al. Association of CCND1 gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis. Int J Clin Exp Med, 2015, 8(8): 12983-8.

    Other cited types(0)

Catalog

    Corresponding author: Xuemei Jia, xmjia@njmu.edu.cn
    • 1.

      Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210004, China

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    Figures(6)  /  Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (700) PDF downloads (381) Cited by(25)
    Related

    ©2025 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return